In a nutshell This study aimed to compare pediatric-inspired intensive therapy and non-intensive therapy for older patients with acute lymphoblastic leukemia. This study concluded that pediatric-inspired intensive therapy improves the outcome for these patients when compared to the non-intensive therapy. Some background Acute lymphoblastic leukemia...
Read More
In a nutshell This study aimed to define therapy goals for major molecular remission in chronic myeloid leukemia. This study concluded that the optimal time for major molecular remission was 12-15 months and if not achieved at this point a change in treatment is needed. Some background Major molecular remission (MMR) is an important therapy goal in...
Read MoreIn a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) in chronic lymphocytic leukemia. This study concluded that long-term administration of ibrutinib was well tolerated and provided effective disease control for most patients. Some background Ibrutinib is a targeted therapy that can be used for...
Read More
In a nutshell This study aimed to investigate the use of stem cell transplant with a chemotherapy treatment regime in patients with acute myeloid leukemia. This study concluded that this regime is safe and effective in patients that receive stem cell transplants from a haploidentical (half or partially matched) donor. Some background The use of...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of nilotinib (Tasigna) in patients with chronic phase chronic myeloid leukemia who have an intolerance to other tyrosine kinase inhibitors. This study concluded that this group of patients can be treated with nilotinib and it can lead to deep molecular responses. Some background...
Read More
In a nutshell This study aimed to investigate risk factors that influence the outcome of acute leukemia patients who experience relapse after hematopoietic stem cell transplant. This study concluded that certain factors, such as older age and not acheiving remission after relapse treatment, are associated with worse survival outcomes. Some...
Read More
The adrenal glands-which are also called suprarenal glands-are part of the endocrine system and are found on the top of each kidney. How the endocrine system hormones work Hormones secreted from glands of the endocrine system travel in the bloodstream to target cells. Target cells have receptors that are specific to each hormone. The hormones and receptors...
Read More
In a nutshell This study examined the long-term safety and effectiveness of bendamustine (Treanda) in lymphoma and leukemia. This study concluded that bendamustine is a safe and effective therapy for these patients. Some background Bendamustine has been shown to have high effectiveness and few side effects for a wide range of lymphomas. This drug is...
Read More
In a nutshell This study outlined recent evidence on the use of ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL). Some background Tyrosine kinase inhibitor therapy is a type of immunotherapy that blocks signals needed for tumors to grow. This includes the Bruton tyrosine kinase inhibitor ibrutinib. Ibrutinib blocks a signal that keeps the...
Read More
In a nutshell This study examined causes and outcomes of a chromosomal abnormality known as 17p deletion in chronic lymphocytic leukemia (CLL). Researchers reported poor outcomes for patients that have both 17p deletion and 8q24 gain. Some background Certain genetic changes in CLL can make it more difficult to treat. Changes in the chromosomes, such...
Read More
In a nutshell This study examined treatment responses to imatinib (Glivec) in chronic myeloid leukemia (CML) patients. Researchers reported that about half of patients achieved an optimal response to treatment that could allow patients to safely stop therapy. Some background Molecular response (MR) is a response to treatment where hardly any or no...
Read More
In a nutshell This study examined a new treatment combination known as RCC followed by rituximab (Rituxan) maintenance therapy for chronic lymphocytic leukemia (CLL). These results support the safety and effectiveness of RCC followed by rituximab maintenance therapy. Risk factors of disease progression were identified. Some background The chemotherapy...
Read More
